Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 2
2003 1
2004 2
2005 1
2006 5
2007 6
2008 6
2009 3
2010 5
2011 10
2012 5
2013 2
2014 2
2015 2
2016 4
2017 3
2018 1
2019 2
2020 2
2021 1
2023 4
2024 5
2025 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

72 results

Results by year

Filters applied: . Clear all
Page 1
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, Fujiwara K, Vergote I, Colombo N, Mäenpää J, Selle F, Sehouli J, Lorusso D, Guerra Alía EM, Reinthaller A, Nagao S, Lefeuvre-Plesse C, Canzler U, Scambia G, Lortholary A, Marmé F, Combe P, de Gregorio N, Rodrigues M, Buderath P, Dubot C, Burges A, You B, Pujade-Lauraine E, Harter P; PAOLA-1 Investigators. Ray-Coquard I, et al. N Engl J Med. 2019 Dec 19;381(25):2416-2428. doi: 10.1056/NEJMoa1911361. N Engl J Med. 2019. PMID: 31851799 Clinical Trial.
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial.
Oaknin A, Gladieff L, Martínez-García J, Villacampa G, Takekuma M, De Giorgi U, Lindemann K, Woelber L, Colombo N, Duska L, Leary A, Godoy-Ortiz A, Nishio S, Angelergues A, Rubio MJ, Fariñas-Madrid L, Yamaguchi S, Lorusso D, Ray-Coquard I, Manso L, Joly F, Alarcón J, Follana P, Romero I, Lebreton C, Pérez-Fidalgo JA, Yunokawa M, Dahlstrand H, D'Hondt V, Randall LM; ENGOT-Cx10–GEICO 68-C–JGOG1084–GOG-3030 Investigators. Oaknin A, et al. Lancet. 2024 Jan 6;403(10421):31-43. doi: 10.1016/S0140-6736(23)02405-4. Epub 2023 Dec 1. Lancet. 2024. PMID: 38048793 Clinical Trial.
Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial.
Harter P, Marth C, Mouret-Reynier MA, Cropet C, Lorusso D, Guerra-Alía EM, Matsumoto T, Vergote I, Colombo N, Mäenpää J, Lebreton C, de Gregorio N, Mosconi AM, Rubio-Pérez MJ, Bourgeois H, Fasching PA, Cecere SC, Hardy-Bessard AC, Denschlag D, de Percin S, Hanker L, Favier L, Bauerschlag D, Desauw C, Hillemanns P, Largillier R, Sehouli J, Grenier J, Pujade-Lauraine E, Ray-Coquard I; PAOLA-1/ENGOT-ov25 investigators. Harter P, et al. Ann Oncol. 2025 Feb;36(2):185-196. doi: 10.1016/j.annonc.2024.10.828. Epub 2024 Nov 9. Ann Oncol. 2025. PMID: 39528049 Free article. Clinical Trial.
Circadian rhythm disruption by PARP inhibitors correlates with treatment toxicity in patients with ovarian cancer and is a predictor of side effects.
Malhan D, Hesse J, Nelson N, Stankov K, Nguyen J, Aboumanify O, Garmshausen J, Rogmans G, Czogalla B, Gerber J, Koch M, Kupec T, Tomé O, Witteler R, Deryal M, Eichbaum M, Sehouli J, Braicu EI, Relógio A. Malhan D, et al. Among authors: eichbaum m. EBioMedicine. 2025 Jul;117:105764. doi: 10.1016/j.ebiom.2025.105764. Epub 2025 May 16. EBioMedicine. 2025. PMID: 40382284 Free PMC article. Clinical Trial.
Lost axillary markers after neoadjuvant chemotherapy in breast cancer patients - data from the prospective international AXSANA (EUBREAST 3) cohort study (NCT04373655).
Hartmann S, Banys-Paluchowski M, Berger T, Ditsch N, Stickeler E, de Boniface J, Gentilini OD, Schroth J, Karadeniz Cakmak G, Rubio IT, Gasparri ML, Kontos M, Bonci EA, Niinikoski L, Murawa D, Kadayaprath G, Pinto D, Peintinger F, Schlichting E, Dostalek L, Nina H, Valiyeva H, Vanhoeij M, Perhavec A, Zippel D, Rebaza LP, Thongvitokomarn S, Fröhlich S, Ruf F, Rief A, Wihlfahrt K, Basali T, Thill M, Lux MP, Loibl S, Kolberg HC, Blohmer JU, Hahn M, Gurleyik MG, Porpiglia M, Gunay S, Zetterlund L, Kuehn T; AXSANA Study Group. Hartmann S, et al. Eur J Surg Oncol. 2025 Sep;51(9):110253. doi: 10.1016/j.ejso.2025.110253. Epub 2025 Jun 25. Eur J Surg Oncol. 2025. PMID: 40587927 Free article.
Statement of the Uterus Commission of the Gynecological Oncology Working Group (AGO) on Neoadjuvant Chemotherapy Prior to Definitive Radiochemotherapy in Patients with Locally Advanced Cervical Cancer.
Tempfer C, Fehm T, Vordermark D, Marnitz-Schulze S, Beckmann MW, Denschlag D, Brucker S, Wallwiener M, Eichbaum M, Ataseven B, Hillemanns P; für die Kommission Uterus der AGO. Tempfer C, et al. Among authors: eichbaum m. Geburtshilfe Frauenheilkd. 2024 Apr 15;84(6):523-528. doi: 10.1055/a-2279-3163. eCollection 2024 Jun. Geburtshilfe Frauenheilkd. 2024. PMID: 38884027 Free PMC article.
Laparoscopic Treatment of an Interstitial Ectopic Pregnancy.
Eichbaum M, Asrar H, Klee A, Eichbaum C. Eichbaum M, et al. J Minim Invasive Gynecol. 2021 Jun;28(6):1135-1136. doi: 10.1016/j.jmig.2020.12.010. Epub 2020 Dec 31. J Minim Invasive Gynecol. 2021. PMID: 33333237 No abstract available.
Impact of metformin, statins, and beta blockers on survival in patients with primary ovarian cancer: combined analysis of four prospective trials of AGO-OVAR and ENGOT/GCIG collaborators.
Denschlag D, Heitz F, Pfisterer J, Tutschkow D, Reuss A, Meier W, Harter P, Wimberger P, Mirza MR, Ray-Coquard I, Scambia G, Kim JW, Colombo N, Oaknin A, Sehouli J, Lindemann K, Lebreton C, Eichbaum M, Spiegelberg S, Woopen H, du Bois A. Denschlag D, et al. Among authors: eichbaum m. Int J Gynecol Cancer. 2024 Dec 2;34(12):1914-1923. doi: 10.1136/ijgc-2024-005663. Int J Gynecol Cancer. 2024. PMID: 39322609
72 results